Our laboratory previously determined that three other miRNAs can be used as immune therapeutics for glioma, including miR-124, which inhibits the signal transducer and activator of transcription 3 (STAT3) [11]; miR-142-3p, which targets the transforming growth factor-β receptor [7]; and miR-138, which can inhibit immune checkpoints [12]. The gene discussed is STAT3; the disease is central nervous system cancer.